Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TMIGD3 | P0DMS9 | 4/20 | 0.56 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.56 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.56 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.53 |
| ▸ | TLR7 | Q9NYK1 | 9/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.48 |
| ▸ | HDAC2 | Q92769 | 4/20 | 0.48 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.46 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.46 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.46 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.46 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.46 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.46 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.46 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.46 |
| ▸ | CDK1 | P06493 | 1/20 | 0.43 |
| ▸ | CDK2 | P24941 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18563908 | 0.88 | TMIGD3 (0.61) | TMIGD3ADORA2AADORA1ADORA2BTLR7 | |
| SCHEMBL18584237 | 0.86 | TMIGD3 (0.59) | TMIGD3ADORA2AADORA1ADORA2BTLR7 | |
| SCHEMBL7206011 | 0.86 | ADORA2A (0.73) | TMIGD3ADORA2AADORA1ADORA2BTLR7 | |
| SCHEMBL12857278 | 0.85 | TMIGD3 (0.52) | TMIGD3ADORA2AADORA1ADORA2BTLR7 | |
| SCHEMBL23421938 | 0.84 | TMIGD3 (0.56) | TMIGD3ADORA2AADORA1ADORA2BTLR7 | |
| SCHEMBL24006833 | 0.84 | TMIGD3 (0.56) | TMIGD3ADORA2AADORA1ADORA2BTLR7 | |
| SCHEMBL24208062 | 0.83 | TMIGD3 (0.58) | TMIGD3ADORA2AADORA1ADORA2BTLR7 | |
| SCHEMBL7204517 | 0.83 | ADORA2A (0.72) | TMIGD3ADORA2AADORA1ADORA2BTLR7 | |
| SCHEMBL15726061 | 0.82 | ADORA2A (0.54) | TMIGD3ADORA2AADORA1ADORA2BTLR7 | |
| SCHEMBL28929629 | 0.82 | TMIGD3 (0.56) | TMIGD3ADORA2AADORA1ADORA2BTLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119455004-A | Compositions, methods and uses comprising antibody-TLR agonist conjugates | AMBRX公司 | 2025-02-18 | — | — | CN | disclosed |
| CN-119455003-A | Compositions, methods and uses comprising antibody-TLR agonist conjugates | AMBRX公司 | 2025-02-18 | — | — | CN | disclosed |
| CN-113660957-B | Compositions, methods and uses comprising antibody-TLR agonist conjugates | AMBRX公司 | 2024-12-13 | — | — | CN | disclosed |
| US-20230302150-A1 | ANTIBODY-TLR AGONIST CONJUGATES, METHODS AND USES THEREOF | AMBRX, INC. (US) | 2023-09-28 | — | — | US | disclosed |
| CN-116457023-A | antibody-TLR agonist conjugates, methods and uses thereof | AMBRX公司 | 2023-07-18 | — | — | CN | disclosed |
| EP-3923991-A1 | COMPOSITIONS CONTAINING, METHODS AND USES OF ANTIBODY-TLR AGONIST CONJUGATES | Ambrx, Inc. (US) | 2021-12-22 | — | — | EP | disclosed |
| CN-113660957-A | Compositions, methods, and uses comprising antibody-TLR agonist conjugates | AMBRX公司 | 2021-11-16 | — | — | CN | disclosed |
| WO-2020168017-A1 | COMPOSITIONS CONTAINING, METHODS AND USES OF ANTIBODY-TLR AGONIST CONJUGATES | AMBRX, INC. (US) | 2020-08-20 | — | — | WO | disclosed |
| WO-2010033074-A1 | USE OF A TLR7 AGONIST FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2010-03-25 | — | — | WO | disclosed |
| WO-2010033074-A1 | USE OF A TLR7 AGONIST FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2010-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230302150-A1 | ANTIBODY-TLR AGONIST CONJUGATES, METHODS AND USES THEREOF | TLR3, TLR1, TLR9 | TMIGD3 210/4885ADORA2A 268/4885ADORA1 546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.